Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma.

NCT00639522 is registered in ClinicalTrials.gov with Nanjing Sike Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00639522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00639522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma.
Lead sponsor
Nanjing Sike Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2008
Completion date
December 31, 2009
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric carcinoma